Parkinson’s Disease, Alzheimer’s, Other Neurological Risks Linked To Air Pollution: Study

Exposure to air pollution may increase the risk of developing serious neurological disorders, such as Parkinson’s disease, Alzheimer’s disease and other dementia problems, according to the findings of a new study.

In findings published last week in the medical journal The Lancet, researchers from Harvard indicate that individuals with higher exposurelevels of fine particulate matter air pollution also had an increased neurological risks, especially if they were over 65 years of age.

Researchers focused on the impact of fine particulate matter 2.5 (PM 2.5) on neurological disorders. Prior research has explored the impact it has on premature death, cardiovascular disease, and respiratory diseases, but not the side effects of air pollution on the brain.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The population-based study involved data on all fee-for-service Medicare beneficiaries over 65 years old in the U.S. from 2000 to 2016. The study included 63 million patients over 65 years old, and researchers estimated PM 2.5 concentrations where they lived based on average annual predictions.

According to the findings, there were one million cases of Parkinson’s disease and 3.4 million cases of Alzheimer’s disease and related dementias, based on primary and secondary diagnosis billing codes.

The data indicates that for each 5 μg/m3 increase in annual PM 2.5 there was a 13% greater risk of hospital admissions for Parkinson’s disease, Alzheimers disease and other dementias. Women, caucasians, and people living in urban areas were especially susceptible.

Those facing the highest risk for Parkinson’s disease were older adults living in the Northeast. People living in the Midwest had the strongest risk for Alzheimer’s or other dementias.

The neurological risk for conditions like Alzheimer’s and Dementia were seen even at levels far below national safety standards. Prior research has also shown air pollution at levels below international standards still posed a risk to human health, even for short-term exposure.

The findings echo other recent research, which has shown exposure to air pollution may increase the risk of cognitive problems and degenerative diseases, such as Alzheimer’s and Dementia. In fact, exposure even at low levels was linked to increased rates of Dementia again in a previous study.

Researchers indicated exposure to air pollution may facilitate biological changes to the body leading to neurodegeneration.

Air pollution kills more than 7 million people each year. Failing to address rising levels of air pollution will continue to affect human health negatively.

“These findings suggest that improving air quality, with PM25 concentrations even lower than current national standards, could yield public health benefits,” the researchers concluded.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.